Joshua Riggs - OncoCyte Corp Interim Officer
| OCXDelisted Stock | USD 3.20 0.43 15.52% |
Insider
Joshua Riggs is Interim Officer of OncoCyte Corp
| Age | 42 |
| Phone | 949 409 7600 |
| Web | https://www.oncocyte.com |
OncoCyte Corp Management Efficiency
The company has Return on Asset of (0.2217) % which means that on every $100 spent on assets, it lost $0.2217. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (4.2896) %, meaning that it generated no profit with money invested by stockholders. OncoCyte Corp's management efficiency ratios could be used to measure how well OncoCyte Corp manages its routine affairs as well as how well it operates its assets and liabilities.OncoCyte Corp has 3.66 M in debt with debt to equity (D/E) ratio of 0.05, which may show that the company is not taking advantage of profits from borrowing. OncoCyte Corp has a current ratio of 3.42, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. That said, strategic use of leverage may enable OncoCyte to fund expansion initiatives and generate superior returns.
Similar Executives
| Found 5 records | INSIDER Age | ||
| LLM LLM | Quince Therapeutics | 54 | |
| Dirk MD | Quince Therapeutics | 56 | |
| Leslie Holsinger | Quince Therapeutics | 59 | |
| Stewart Low | Quince Therapeutics | N/A | |
| Ted Monohon | Quince Therapeutics | 58 | |
Management Performance
| Return On Equity | -4.29 | |||
| Return On Asset | -0.22 |
OncoCyte Corp Leadership Team
Elected by the shareholders, the OncoCyte Corp's board of directors comprises two types of representatives: OncoCyte Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OncoCyte. The board's role is to monitor OncoCyte Corp's management team and ensure that shareholders' interests are well served. OncoCyte Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OncoCyte Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrea James, Chief Officer | ||
| Michael West, Director, CEO of Biotime Inc and President of Biotime Inc | ||
| Ekkehard MD, Chief Officer | ||
| Joshua Riggs, Interim Officer | ||
| Tony Kalajian, Senior Vice President Chief Accounting Officer | ||
| Andrew Last, Independent Director | ||
| William Annett, Advisor | ||
| Gabrielle Woody, Executive Assistant | ||
| Sara Riordan, Director Education | ||
| Albert Parker, Chief Operating Officer | ||
| Lyndal Hesterberg, Chief Scientific Officer | ||
| Robert Seitz, Head Oncology | ||
| James Liu, Treasurer, Accounting | ||
| YuhMin Chiang, Senior Development | ||
| Douglas Ross, Chief Medical Officer | ||
| Melinda Griffith, Independent Director | ||
| Anish John, Chief Officer | ||
| Peter Hong, General VP | ||
| Andrew Arno, Independent Director | ||
| Gisela Paulsen, COO Pres | ||
| Ronald Andrews, President, Chief Executive Officer, Director | ||
| Cavan Redmond, Independent Chairman of the Board | ||
| Padma Sundar, Senior Vice President - Marketing and Market Access | ||
| MD FACP, Consulting Officer | ||
| Mitchell Levine, Chief Financial Officer | ||
| Sandra ODonald, Senior Operations |
OncoCyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OncoCyte Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.29 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (2.73) % | |||
| Current Valuation | 63.97 M | |||
| Shares Outstanding | 28.6 M | |||
| Shares Owned By Insiders | 22.03 % | |||
| Shares Owned By Institutions | 56.30 % | |||
| Number Of Shares Shorted | 265.49 K | |||
| Price To Earning | (12.20) X | |||
| Price To Book | 8.96 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in OncoCyte Stock
If you are still planning to invest in OncoCyte Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the OncoCyte Corp's history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |